2018
Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards
Cooper M, Formica R, Friedewald J, Hirose R, O’Connor K, Mohan S, Schold J, Axelrod D, Pastan S. Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards. Clinical Transplantation 2018, 33: e13419. PMID: 30345720, DOI: 10.1111/ctr.13419.Peer-Reviewed Original ResearchAnalysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes
Faddoul G, Nadkarni GN, Bridges ND, Goebel J, Hricik DE, Formica R, Menon MC, Morrison Y, Murphy B, Newell K, Nickerson P, Poggio ED, Rush D, Heeger PS. Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. Transplantation 2018, 102: 673-680. PMID: 29189482, PMCID: PMC6018026, DOI: 10.1097/tp.0000000000002026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersChemokine CXCL9Enzyme-Linked Immunospot AssayFemaleGlomerular Filtration RateGraft RejectionGraft SurvivalHumansInterferon-gammaInterferon-gamma Release TestsKidneyKidney TransplantationMaleMiddle AgedNorth AmericaPredictive Value of TestsProspective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsEnzyme-linked immunosorbent spotGraft lossAcute cellular rejectionKidney allograft lossKidney transplant outcomesGlomerular filtration rateMultivariable logistic regressionAllograft lossCellular rejectionCXCL9 levelsUrinary CXCL9Year posttransplantTransplant outcomesImmunosorbent spotUnivariable analysisChemokine measurementsFiltration rateSurrogate markerClinical trialsLate outcomesOrgan transplantationT cellsInterferon gammaAnalysis of biomarkersLogistic regressionSolid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients
Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Current Opinion In Organ Transplantation 2018, 23: 257-263. PMID: 29432255, DOI: 10.1097/mot.0000000000000504.Peer-Reviewed Original ResearchConceptsViremic donorsHepatitis CWaitlist mortalityHepatitis C viremic donorsEarly trial dataHCV-negative recipientsTransplantation of graftsHepatitis C therapySolid organ transplantsSolid organ transplantationUtilization of graftsFormal clinical trialsNet overall reductionGraft utilizationNonviremic recipientsTransplant recipientsC therapyNegative patientsAntiviral therapyNegative recipientsTransplantation ratesClinical trialsOrgan poolDonor organsOrgan transplantation
2017
The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation
Levitsky J, Formica R, Bloom R, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O’Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. American Journal Of Transplantation 2017, 17: 2790-2802. PMID: 28556422, DOI: 10.1111/ajt.14381.Peer-Reviewed Original ResearchConceptsSolid organ transplantationOrgan transplantationHepatitis C viremic donorsHepatitis C virus infectionEnd-stage organ diseaseHCV-viremic organsHCV-viremic patientsProspective research protocolC virus infectionChronic HCV infectionAmerican SocietyViremic donorsViremic organsViremic recipientsHCV infectionHepatitis CTransplant waitlistMeeting of expertsOrgan diseaseVirus infectionOrgan transplantsYoung donorsAntiviral agentsConsensus conferenceTransplantation
2002
Evolving role of sirolimus immunosuppression after organ transplantation
Formica R, Friedman A, Lorber M. Evolving role of sirolimus immunosuppression after organ transplantation. Current Opinion In Organ Transplantation 2002, 7: 353-358. DOI: 10.1097/00075200-200212000-00009.Peer-Reviewed Original ResearchCalcineurin inhibitorsOrgan transplantationG1-S phase cell cycle arrestHigher serum creatinine valuesBiologic side effectsSirolimus-treated patientsCalcineurin inhibitor tacrolimusSerum creatinine valuesPivotal clinical trialsReduced rejection ratesPhase cell cycle arrestAllograft arteriosclerosisSirolimus immunosuppressionTriglyceride elevationLymphocele formationSirolimus useReversible thrombocytopeniaSerum cholesterolCreatinine valuesCell cycle arrestClinical trialsSide effectsSirolimusComplex woundsFull dose